Pfizer is almost finished enrolling volunteers in its Phase 3 clinical trial of a Covid-19 vaccine.
The company has stated it plans to enroll approximately 44,000 participants. On Monday, it announced the addition of 270 more volunteers, bringing the current enrollment to 43,931 people.
More than 42,722 participants have received their second vaccination.
A final analysis of the Phase 3 trial of Pfizer's coronavirus vaccine showed it was 95% effective in preventing infections and caused no serious safety concerns, the company said previously.